biostudies-literatureUnknown56(6)Lavu A<b>Purpose:</b> A 28-year-old male reported to our hospital with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap syndrome that developed as an adverse drug reaction (ADR) to allopurinol. <i>HLA-B*58:01</i> allele is associated with an increased risk of developing allopurinol-induced SJS/TEN. <b>Methods:</b> Genomic DNA was extracted from peripheral blood leukocytes. DNA sequencing was done using SANGER sequencing method. <b>Results:</b> Pharmacogenetic testing results revealed positive for <i>HLA-B*58:01</i> allele. Symptoms of the patient receded after allopurinol withdrawal. <b>Conclusion:</b> The thrust of personalized therapy is from decoding the individual specific genetic variations astutely for better therapeutic outcomes such as reducing the ADRs. Pharmacogenetic testing is emerging as a safe, fast, and economic screening tool for personalized therapy by preventing ADRs. Pharmacogenetic <i>HLA-B*58:01</i> allele testing before allopurinol administration could significantly reduce the incidence of SJS/TEN and associated mortalities/morbidities and thereby represent a potential cost-effective intervention.Hospital pharmacy660-663https://www.ebi.ac.uk/biostudies/studies/S-EPMC8559029biostudies-literatureClinical Utility of <i>HLA-B*58:01</i> Genotyping to Prevent Allopurinol-Induced SJS/TEN.PMC8559029Thomas LSaravu KLavu AThiriveedi SRao MKhera KfalseClinical Utility of <i>HLA-B*58:01</i> Genotyping to Prevent Allopurinol-Induced SJS/TEN.<b>Purpose:</b> A 28-year-old male reported to our hospital with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) overlap syndrome that developed as an adverse drug reaction (ADR) to allopurinol. <i>HLA-B*58:01</i> allele is associated with an increased risk of developing allopurinol-induced SJS/TEN. <b>Methods:</b> Genomic DNA was extracted from peripheral blood leukocytes. DNA sequencing was done using SANGER sequencing method. <b>Results:</b> Pharmacogenetic testing results revealed positive for <i>HLA-B*58:01</i> allele. Symptoms of the patient receded after allopurinol withdrawal. <b>Conclusion:</b> The thrust of personalized therapy is from decoding the individual specific genetic variations astutely for better therapeutic outcomes such as reducing the ADRs. Pharmacogenetic testing is emerging as a safe, fast, and economic screening tool for personalized therapy by preventing ADRs. Pharmacogenetic <i>HLA-B*58:01</i> allele testing before allopurinol administration could significantly reduce the incidence of SJS/TEN and associated mortalities/morbidities and thereby represent a potential cost-effective intervention.2021-01-01T00:00:00Z2021 Dec2025-04-26T09:45:26.921Z2025-04-06T13:07:42.011ZS-EPMC85590293473291810.1177/0018578720934972